GLP1R and type 2 diabetes mellitus: Notably, genetically-proxied GLP-1 RA exposure was significantly associated with decreased HbA1c levels [OR (95%) = 0.90 (0.89-0.92), P < 0.001], reduced type 2 diabetes risk [OR (95%) = 0.80 (0.76-0.84), P < 0.001], and lower BMI [OR (95%) = 0.98 (0.96-0.99), P = 0.0026], confirming the validity of the IVs (see Table S5).